![Ton Adang](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ton Adang
Corporate Officer/Principal bei LAVA THERAPEUTICS N.V.
Vermögen: 1 808 $ am 31.05.2024
Aktive Positionen von Ton Adang
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
LAVA THERAPEUTICS N.V. | Corporate Officer/Principal | 01.07.2017 | - |
Karriereverlauf von Ton Adang
Ehemalige bekannte Positionen von Ton Adang
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
EnCare Biotech BV
![]() EnCare Biotech BV Medical/Nursing ServicesHealth Services EnCare Biotech BV operates as a biopharmaceutical company which develops therapeutic antibody for the prevention of heart failure after acute myocardial infarction. Its product is a novel therapeutic monoclonal antibody against the EDA fragment of fibronectin. The company was founded by Fatih Arslan in 2014 and is headquartered in Utrecht, the Netherlands. | Geschäftsführer | 01.08.2014 | 01.12.2017 |
Fast Forward Pharmaceuticals BV
![]() Fast Forward Pharmaceuticals BV Medical SpecialtiesHealth Technology Fast Forward Pharmaceuticals BV develops novel disease-modifying therapeutics for the treatment of inflammatory and autoimmune diseases. It is developing an anti-CD40 monoclonal antibody therapy for the treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn’s disease. The company was founded by Louis Boon in October 2010 and is headquartered in Utrecht, Netherlands. | Geschäftsführer | 01.10.2012 | 01.10.2017 |
AM-Pharma BV
![]() AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Corporate Officer/Principal | 01.08.2014 | 01.09.2016 |
Simibio BV
![]() Simibio BV BiotechnologyHealth Technology Simibio BV develops therapeutic monoclonal antibodies. It serves the pharmaceutical industry. The company was founded in 2010 by Mark de Boer and is headquartered in Utrecht, the Netherlands. | Geschäftsführer | 01.07.2011 | 01.06.2014 |
MERCK KGAA | Corporate Officer/Principal | 01.11.2009 | 01.03.2010 |
Ausbildung von Ton Adang
Wageningen University | Graduate Degree |
University of Leiden | Doctorate Degree |
Statistik
International
Niederlande | 8 |
Deutschland | 2 |
Operativ
Chief Operating Officer | 3 |
Corporate Officer/Principal | 3 |
Graduate Degree | 1 |
Sektoral
Health Technology | 6 |
Consumer Services | 3 |
Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
LAVA THERAPEUTICS N.V. | Health Technology |
MERCK KGAA | Health Technology |
Private Unternehmen | 4 |
---|---|
Simibio BV
![]() Simibio BV BiotechnologyHealth Technology Simibio BV develops therapeutic monoclonal antibodies. It serves the pharmaceutical industry. The company was founded in 2010 by Mark de Boer and is headquartered in Utrecht, the Netherlands. | Health Technology |
EnCare Biotech BV
![]() EnCare Biotech BV Medical/Nursing ServicesHealth Services EnCare Biotech BV operates as a biopharmaceutical company which develops therapeutic antibody for the prevention of heart failure after acute myocardial infarction. Its product is a novel therapeutic monoclonal antibody against the EDA fragment of fibronectin. The company was founded by Fatih Arslan in 2014 and is headquartered in Utrecht, the Netherlands. | Health Services |
Fast Forward Pharmaceuticals BV
![]() Fast Forward Pharmaceuticals BV Medical SpecialtiesHealth Technology Fast Forward Pharmaceuticals BV develops novel disease-modifying therapeutics for the treatment of inflammatory and autoimmune diseases. It is developing an anti-CD40 monoclonal antibody therapy for the treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn’s disease. The company was founded by Louis Boon in October 2010 and is headquartered in Utrecht, Netherlands. | Health Technology |
AM-Pharma BV
![]() AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Health Technology |